How do histamine H1‑receptor antagonists provide dual benefit by blocking the renogastric reflex in renal or ureteric colic?

Histamine H1 Receptor Antagonists in Renal Colic: Dual Mechanism of Action

Histamine H1 receptor antagonists like dimenhydrinate provide dual benefit in renal colic by directly blocking H1 receptors in the ureter to reduce smooth muscle contraction and pain, while simultaneously treating the nausea and vomiting that commonly accompany renal colic through central antiemetic effects.

The Renogastric Reflex and H1 Receptor Mechanism

The pathophysiology of renal colic involves more than just mechanical obstruction. When a stone obstructs the ureter, it triggers:

• Prostaglandin surge leading to arterial vasodilation and increased vascular permeability 1
• Ureteric edema and spasms from this inflammatory cascade 1
• Histamine release that contributes to both pain and the gastrointestinal symptoms

Direct Ureteric Effects

H1 receptors are widely distributed throughout the ureter 2. When activated by histamine during ureteral obstruction, these receptors cause:

• Smooth muscle contractions that worsen colic pain
• Enhanced prostaglandin-mediated renal vasodilation 3

Blocking H1 receptors with antagonists like dimenhydrinate directly reduces ureteral smooth muscle contraction and attenuates the prostaglandin-induced vasodilatory response 3. In experimental models, H1 antagonists blocked ureteral occlusion-induced renal vasodilation and markedly attenuated prostaglandin E2, I2, and A2-induced increases in renal blood flow 3.

Antiemetic Effects

The second benefit is straightforward: H1 antagonists like dimenhydrinate (an ethanolamine group H1 blocker) have well-established central antiemetic properties that directly address the nausea and vomiting accompanying renal colic 2.

Clinical Evidence

A randomized, double-blind, placebo-controlled trial demonstrated that 50 mg intramuscular dimenhydrinate was statistically superior to placebo in reducing both pain (measured by VAS) and nausea/vomiting (measured by VDS) at 10,20, and 30 minutes after administration 2. This study included 86 patients with renal colic accompanied by nausea, showing significant improvements in both pain and gastrointestinal symptoms 2.

Important Clinical Context

Current Guideline Recommendations

The 2025 EAU guidelines establish NSAIDs (diclofenac, ibuprofen, metamizole) as first-line treatment for renal colic, with opioids as second-choice analgesics 4. NSAIDs work by reducing prostaglandin-mediated inflammation and lowering pressure in the urinary collecting system 5.

Where H1 Antagonists Fit

While H1 antagonists are not mentioned in current EAU guidelines as primary analgesics 4, they offer a rational adjunctive approach when:

• Nausea and vomiting are prominent symptoms requiring treatment
• NSAIDs are contraindicated (cardiovascular risk, gastrointestinal risk, renal impairment) 4
• Additional pain control is needed beyond standard therapy

Clinical Caveats

• H1 antagonists should not replace NSAIDs as first-line therapy based on current guideline recommendations 4
• The evidence for H1 antagonists comes from limited studies 2, 3, whereas NSAIDs have robust evidence from multiple RCTs 5
• Comparative studies with standard analgesics are needed to determine the optimal role of H1 antagonists 2
• Consider sedation as a potential side effect when using H1 antagonists

Practical Algorithm

For renal colic with nausea:

1. First-line: NSAID (diclofenac 50-75 mg IM/IV or ibuprofen 800 mg PO) 4
2. Add: H1 antagonist (dimenhydrinate 50 mg IM) for dual pain relief and antiemetic effect 2
3. If inadequate: Consider opioid (avoid pethidine; use hydromorphine, pentazocine, or tramadol) 4
4. If stone >5 mm in distal ureter: Add alpha-blocker for medical expulsive therapy 4

The dual mechanism makes H1 antagonists particularly attractive as adjunctive therapy when nausea accompanies renal colic, addressing two symptoms with one medication while potentially reducing opioid requirements.